Spotlight on Family Medicine
Case-in-Point™ − Cause for Alarm: New Avenues to the Management of Severe Asthma
StartActivity Details
1.0 AANP Contact Hour(s)
Expires: January 18, 2023
Provided By
This activity is jointly provided by Global Education Group and Integritas
Communications.
Target Audience
This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
- Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
- Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
- Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences
Activity Description
Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all of which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies.
Moderator

Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey
Faculty

Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology – Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Reynold A. Panettieri, Jr, MD: Consulting Fee: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Contracted Research: ACTIV-1, AstraZeneca plc, Genentech, Inc., Janssen Pharmaceuticals, Medimmune, LLC, Novartis International AG, Origo Biopharma, Teva Pharmaceutical Industries Ltd., Vault Health, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Merck & Co., Inc., Sanofi S.A.
Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Sanofi S.A.; Contracted Research: ALA Pharma Ltd., AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.
Anju T. Peters, MD, MS: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis International AG, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Merck & Co., Inc., Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.
The following planners and managers have reported no relevant financial relationships with ineligible companies:
Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in
accordance with the Accreditation Standards of the American Association of
Nurse Practitioners (AANP) through the joint providership of Global Education
Group and Integritas Communications. Global Education Group is accredited by
the American Association of Nurse Practitioners as an approved provider of
nurse practitioner continuing education. Provider number: 110121. This
activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of
pharmacology).
Instructions for Receiving Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the post-test, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. Global and
Integritas Communications do not recommend the use of any agent outside of
the labeled indications.
The opinions expressed in the educational activity are those of the faculty
and do not necessarily represent the views of any organization associated
with this activity. Please refer to the official prescribing information for
each product for discussion of approved indications, contraindications, and
warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Term of Offering
This activity was released on January 18, 2022, and is valid for one year. Requests for credit must be made no later than January 18, 2023.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
Global Contact Information
For information about the accreditation of this program, please contact
Global at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
1.0 AANP Contact Hour(s)
Expires: January 18, 2023
Provided By
This activity is jointly provided by Global Education Group and Integritas
Communications.
Target Audience
This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
- Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
- Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
- Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences
Activity Description
Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all of which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies.
Moderator

Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey
Faculty

Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology – Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Reynold A. Panettieri, Jr, MD: Consulting Fee: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Contracted Research: ACTIV-1, AstraZeneca plc, Genentech, Inc., Janssen Pharmaceuticals, Medimmune, LLC, Novartis International AG, Origo Biopharma, Teva Pharmaceutical Industries Ltd., Vault Health, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Merck & Co., Inc., Sanofi S.A.
Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Sanofi S.A.; Contracted Research: ALA Pharma Ltd., AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.
Anju T. Peters, MD, MS: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis International AG, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Merck & Co., Inc., Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.
The following planners and managers have reported no relevant financial relationships with ineligible companies:
Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in
accordance with the Accreditation Standards of the American Association of
Nurse Practitioners (AANP) through the joint providership of Global Education
Group and Integritas Communications. Global Education Group is accredited by
the American Association of Nurse Practitioners as an approved provider of
nurse practitioner continuing education. Provider number: 110121. This
activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of
pharmacology).
Instructions for Receiving Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the post-test, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. Global and
Integritas Communications do not recommend the use of any agent outside of
the labeled indications.
The opinions expressed in the educational activity are those of the faculty
and do not necessarily represent the views of any organization associated
with this activity. Please refer to the official prescribing information for
each product for discussion of approved indications, contraindications, and
warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Term of Offering
This activity was released on January 18, 2022, and is valid for one year. Requests for credit must be made no later than January 18, 2023.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
Global Contact Information
For information about the accreditation of this program, please contact
Global at 303-395-1782 or cme@globaleducationgroup.com.
Family Medicine Presentations

The Increasingly Vital Role of Early Alzheimer’s Disease Diagnosis & Treatment in Averting the Amyloid Tipping Point
StartActivity Details
0.5 AAFP Prescribed Credit(s)
Expires: April 14, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for neurology and primary care clinicians (MD/DO/NP/PA) engaged in the care of patients with Alzheimer’s disease.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify mild cognitive impairment and early Alzheimer’s disease with the help of screening tools, biomarkers, and neuroimaging techniques
- Integrate approved and emerging anti-amyloid β therapies for the treatment of mild cognitive impairment and early-stage Alzheimer’s disease
Activity Description
Alzheimer’s disease (AD) is a growing public health concern, and as the aging population rapidly increases, so too does the number of individuals affected by AD. The recent availability of therapy for mild cognitive impairment (MCI) and early-stage AD has increased the need for early screening. In this uniquely designed, reflective activity, learners are presented with 2 cases related to AD and challenged to think about how the patients could have been better assessed/managed. A multidisciplinary discussion between a primary care physician (PCP) and neurologist will combine elements of cognitive assessment, proper screening and referral, and early management to demonstrate the critical relationship PCPs and neurologists have in identifying and managing patients with MCI/early-stage AD.
Chair

Professor, Neurology
Barrow Neurological Institute
Phoenix, AZ
Faculty

Professor Emeritus, University of Mississippi Medical Center
Chief Health Officer, The Jones Group of Mississippi
Jackson, MS
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Warren A. Jones, MD, FAAFP, has no relevant financial relationship(s) with ineligible companies to disclose.
Marwan Noel Sabbagh, MD, FAAN, has relevant financial relationships with Acadia Pharmaceuticals, Alzheon, Biogen, Cortexyme, Eisai, Eli Lilly, Genentech, KeifeRx, Qynapse, Renew Research, T3D Therapeutics (Consultant); Athira, Brain Health Inc., Cognoptix, NeuroTau, Optimal Cognitive Health Company, TransDermix, uMethod Health, Versanum (Stock/Shareholder); Clinical Options, Health and Wellness Partners (Speaker/Speaker’s Bureau); Humanix (Other: Royalties).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
AAFP Prescribed Credits
The AAFP
has reviewed The Increasingly Vital Role of Early Alzheimer’s Disease
Diagnosis & Treatment in Averting the Amyloid Tipping Point and deemed it
acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed
credits. Term of Approval is from 04/15/2022 to 04/14/2023. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent educational grant from Biogen MA, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.5 AAFP Prescribed Credit(s)
Expires: April 14, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for neurology and primary care clinicians (MD/DO/NP/PA) engaged in the care of patients with Alzheimer’s disease.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify mild cognitive impairment and early Alzheimer’s disease with the help of screening tools, biomarkers, and neuroimaging techniques
- Integrate approved and emerging anti-amyloid β therapies for the treatment of mild cognitive impairment and early-stage Alzheimer’s disease
Activity Description
Alzheimer’s disease (AD) is a growing public health concern, and as the aging population rapidly increases, so too does the number of individuals affected by AD. The recent availability of therapy for mild cognitive impairment (MCI) and early-stage AD has increased the need for early screening. In this uniquely designed, reflective activity, learners are presented with 2 cases related to AD and challenged to think about how the patients could have been better assessed/managed. A multidisciplinary discussion between a primary care physician (PCP) and neurologist will combine elements of cognitive assessment, proper screening and referral, and early management to demonstrate the critical relationship PCPs and neurologists have in identifying and managing patients with MCI/early-stage AD.
Chair

Professor, Neurology
Barrow Neurological Institute
Phoenix, AZ
Faculty

Professor Emeritus, University of Mississippi Medical Center
Chief Health Officer, The Jones Group of Mississippi
Jackson, MS
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Warren A. Jones, MD, FAAFP, has no relevant financial relationship(s) with ineligible companies to disclose.
Marwan Noel Sabbagh, MD, FAAN, has relevant financial relationships with Acadia Pharmaceuticals, Alzheon, Biogen, Cortexyme, Eisai, Eli Lilly, Genentech, KeifeRx, Qynapse, Renew Research, T3D Therapeutics (Consultant); Athira, Brain Health Inc., Cognoptix, NeuroTau, Optimal Cognitive Health Company, TransDermix, uMethod Health, Versanum (Stock/Shareholder); Clinical Options, Health and Wellness Partners (Speaker/Speaker’s Bureau); Humanix (Other: Royalties).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
AAFP Prescribed Credits
The AAFP
has reviewed The Increasingly Vital Role of Early Alzheimer’s Disease
Diagnosis & Treatment in Averting the Amyloid Tipping Point and deemed it
acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed
credits. Term of Approval is from 04/15/2022 to 04/14/2023. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent educational grant from Biogen MA, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Case-in-Point™ − Cause for Alarm: New Avenues to the Management of Severe Asthma
StartActivity Details
1.0 AANP Contact Hour(s)
Expires: January 18, 2023
Provided By
This activity is jointly provided by Global Education Group and Integritas
Communications.
Target Audience
This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
- Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
- Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
- Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences
Activity Description
Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all of which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies.
Moderator

Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey
Faculty

Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology – Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Reynold A. Panettieri, Jr, MD: Consulting Fee: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Contracted Research: ACTIV-1, AstraZeneca plc, Genentech, Inc., Janssen Pharmaceuticals, Medimmune, LLC, Novartis International AG, Origo Biopharma, Teva Pharmaceutical Industries Ltd., Vault Health, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Merck & Co., Inc., Sanofi S.A.
Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Sanofi S.A.; Contracted Research: ALA Pharma Ltd., AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.
Anju T. Peters, MD, MS: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis International AG, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Merck & Co., Inc., Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.
The following planners and managers have reported no relevant financial relationships with ineligible companies:
Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in
accordance with the Accreditation Standards of the American Association of
Nurse Practitioners (AANP) through the joint providership of Global Education
Group and Integritas Communications. Global Education Group is accredited by
the American Association of Nurse Practitioners as an approved provider of
nurse practitioner continuing education. Provider number: 110121. This
activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of
pharmacology).
Instructions for Receiving Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the post-test, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. Global and
Integritas Communications do not recommend the use of any agent outside of
the labeled indications.
The opinions expressed in the educational activity are those of the faculty
and do not necessarily represent the views of any organization associated
with this activity. Please refer to the official prescribing information for
each product for discussion of approved indications, contraindications, and
warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Term of Offering
This activity was released on January 18, 2022, and is valid for one year. Requests for credit must be made no later than January 18, 2023.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
Global Contact Information
For information about the accreditation of this program, please contact
Global at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
1.0 AANP Contact Hour(s)
Expires: January 18, 2023
Provided By
This activity is jointly provided by Global Education Group and Integritas
Communications.
Target Audience
This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
- Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
- Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
- Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences
Activity Description
Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all of which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies.
Moderator

Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey
Faculty

Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology – Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Reynold A. Panettieri, Jr, MD: Consulting Fee: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Contracted Research: ACTIV-1, AstraZeneca plc, Genentech, Inc., Janssen Pharmaceuticals, Medimmune, LLC, Novartis International AG, Origo Biopharma, Teva Pharmaceutical Industries Ltd., Vault Health, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Merck & Co., Inc., Sanofi S.A.
Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Sanofi S.A.; Contracted Research: ALA Pharma Ltd., AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.
Anju T. Peters, MD, MS: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis International AG, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Merck & Co., Inc., Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.
The following planners and managers have reported no relevant financial relationships with ineligible companies:
Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in
accordance with the Accreditation Standards of the American Association of
Nurse Practitioners (AANP) through the joint providership of Global Education
Group and Integritas Communications. Global Education Group is accredited by
the American Association of Nurse Practitioners as an approved provider of
nurse practitioner continuing education. Provider number: 110121. This
activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of
pharmacology).
Instructions for Receiving Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the post-test, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. Global and
Integritas Communications do not recommend the use of any agent outside of
the labeled indications.
The opinions expressed in the educational activity are those of the faculty
and do not necessarily represent the views of any organization associated
with this activity. Please refer to the official prescribing information for
each product for discussion of approved indications, contraindications, and
warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Term of Offering
This activity was released on January 18, 2022, and is valid for one year. Requests for credit must be made no later than January 18, 2023.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
Global Contact Information
For information about the accreditation of this program, please contact
Global at 303-395-1782 or cme@globaleducationgroup.com.

Paths to Functional Recovery in Major Depressive Disorder: Putting the Patient First – Combining Patient-Centered Care for Major Depressive Disorder with the Latest Antidepressant Efficacy to Optimize Treatment Plans
StartActivity Details
0.5 Contact Hour(s)
Expires: January 25, 2023
Jointly Provided By
This activity is jointly provided by Medical Education Resources and CMEology.
Target Audience
Psychiatrists and advanced practice psychiatry clinicians who care for patients with major depressive disorder.
Learning Objectives
- Incorporate patient preferences, values, and goals when developing a care plan
- Evaluate patients being treated for MDD to identify the presence of residual symptoms, such as cognitive dysfunction
- Assess treatment strategies for a patient with MDD that will maximize their quality of life and functional recovery
Activity Description
This is one of two related online multimedia activities designed to assess and enhance clinical decision-making through immersive, interactive learning. Participants will use realistic “near-life” education as they make decisions for what comes next – just like real life.
Statement of Educational Need
Only roughly half of patients with MDD achieve recovery after 6 months of treatment. The others continue to experience residual symptoms that impair their ability to function at work, school, and home. To ensure that more patients with MDD achieve functional recovery, clinicians require practical information about how to provide early, optimized care. In this activity, an expert faculty member will support learners as they are asked to track patients’ response to treatment and detect and manage common residual MDD symptoms. Two cases will be used to illustrate how to individualize MDD care to maximize patients’ chances of recovery.
Learning Goal/Purpose
The goal of this activity is to increase clinicians’ knowledge and competence
with regard to optimizing MDD treatment plans, thus increasing the proportion
of patients with MDD who are able to achieve functional recovery.
Agenda
- Prevalence of major depressive disorder since COVID-19 pandemic
- Functional recovery and the importance of helping patients move beyond symptom remission
- Case study, functional recovery and shared decision-making
- Residual symptoms that frequently impede functional recovery
- Case study, residual symptoms
- Strategies for managing residual symptoms and responding to insufficient progress toward functional recovery
Faculty

Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania
Conflict of Interest Policy/Disclosure Statement
Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Advisory/Consultant: Acadia, Inc.; Akili, Inc.; Alkermes PLC;
Allergan, Inc. (Forest, Naurex); Clexio Biosciences, Ltd.; H. Lundbeck, A/S;
Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.;
Otsuka Pharmaceutical Company, Ltd.; Pfizer, Inc.; Seelos
Grant Support: Acadia, Inc.; Allergan, Inc.; Axsome Therapeutics
Inc.; Intracellular, Inc.; Johnson & Johnson (Janssen); Otsuka Pharmaceutical
Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI);
Takeda
Royalties: American Psychiatric Press; Guilford Publications; Herald
House; W.W. Norton & Company, Inc.; Wolters Kluwer
CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.
Accreditation Statement
This
activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of
Medical Education Resources (MER) and CMEology. MER is accredited by the
ACCME to provide continuing medical education for physicians.
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CE activity provides 0.5 contact hour(s) of continuing nursing education.
Instructions for Receiving Credit
There are no fees for participating in and receiving credit for this activity. During the period January 25, 2022 through January 25, 2023, participants must (1) read the learning objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest by recording the best answer to each question, and (4) complete the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.
Statement of Commercial Support
This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.
Activity Details
0.5 Contact Hour(s)
Expires: January 25, 2023
Jointly Provided By
This activity is jointly provided by Medical Education Resources and CMEology.
Target Audience
Psychiatrists and advanced practice psychiatry clinicians who care for patients with major depressive disorder.
Learning Objectives
- Incorporate patient preferences, values, and goals when developing a care plan
- Evaluate patients being treated for MDD to identify the presence of residual symptoms, such as cognitive dysfunction
- Assess treatment strategies for a patient with MDD that will maximize their quality of life and functional recovery
Activity Description
This is one of two related online multimedia activities designed to assess and enhance clinical decision-making through immersive, interactive learning. Participants will use realistic “near-life” education as they make decisions for what comes next – just like real life.
Statement of Educational Need
Only roughly half of patients with MDD achieve recovery after 6 months of treatment. The others continue to experience residual symptoms that impair their ability to function at work, school, and home. To ensure that more patients with MDD achieve functional recovery, clinicians require practical information about how to provide early, optimized care. In this activity, an expert faculty member will support learners as they are asked to track patients’ response to treatment and detect and manage common residual MDD symptoms. Two cases will be used to illustrate how to individualize MDD care to maximize patients’ chances of recovery.
Learning Goal/Purpose
The goal of this activity is to increase clinicians’ knowledge and competence
with regard to optimizing MDD treatment plans, thus increasing the proportion
of patients with MDD who are able to achieve functional recovery.
Agenda
- Prevalence of major depressive disorder since COVID-19 pandemic
- Functional recovery and the importance of helping patients move beyond symptom remission
- Case study, functional recovery and shared decision-making
- Residual symptoms that frequently impede functional recovery
- Case study, residual symptoms
- Strategies for managing residual symptoms and responding to insufficient progress toward functional recovery
Faculty

Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania
Conflict of Interest Policy/Disclosure Statement
Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Advisory/Consultant: Acadia, Inc.; Akili, Inc.; Alkermes PLC;
Allergan, Inc. (Forest, Naurex); Clexio Biosciences, Ltd.; H. Lundbeck, A/S;
Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.;
Otsuka Pharmaceutical Company, Ltd.; Pfizer, Inc.; Seelos
Grant Support: Acadia, Inc.; Allergan, Inc.; Axsome Therapeutics
Inc.; Intracellular, Inc.; Johnson & Johnson (Janssen); Otsuka Pharmaceutical
Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI);
Takeda
Royalties: American Psychiatric Press; Guilford Publications; Herald
House; W.W. Norton & Company, Inc.; Wolters Kluwer
CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.
Accreditation Statement
This
activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of
Medical Education Resources (MER) and CMEology. MER is accredited by the
ACCME to provide continuing medical education for physicians.
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CE activity provides 0.5 contact hour(s) of continuing nursing education.
Instructions for Receiving Credit
There are no fees for participating in and receiving credit for this activity. During the period January 25, 2022 through January 25, 2023, participants must (1) read the learning objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest by recording the best answer to each question, and (4) complete the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.
Statement of Commercial Support
This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Paths to Functional Recovery in Major Depressive Disorder: Putting the Patient First – A Patient-Centered Approach to Preventing, Detecting, and Managing Adverse Effects of Antidepressants
StartActivity Details
0.5 Contact Hour(s)
Expires: January 25, 2023
Jointly Provided By
This activity is jointly provided by Medical Education Resources and CMEology.
Target Audience
Psychiatrists and advanced practice psychiatry clinicians who care for patients with major depressive disorder.
Learning Objectives
- Evaluate patients being treated for MDD to identify common adverse effects such as sexual dysfunction, weight gain, and sleep disturbance
- Assess treatment strategies for a patient with MDD who is experiencing an adverse effect on their current MDD therapy
Activity Description
This is one of two related online multimedia activities designed to assess and enhance clinical decision-making through immersive, interactive learning. Participants will use realistic “near-life” education as they make decisions for what comes next – just like real life.
Statement of Educational Need
Adverse effects associated with antidepressants are common. In addition to compromising patients’ health and quality of life, they are one of the most common reasons that individuals with MDD fail to adhere to their treatment plans. To minimize the impact of antidepressant side effects on the lives of patients with MDD, clinicians require education on how to prevent, detect, and manage the most common adverse effects caused by these medications. In this activity, an expert faculty member will support learners as they are asked to respond to patients experiencing side effects related to their antidepressant use. Two cases will be used to illustrate how a patient-centered approach to MDD care can maximize treatment tolerability.
Learning Goal/Purpose
The goal of this activity is to increase clinicians’ knowledge and competence
with regard to preventing, detecting, and managing antidepressant side
effects, thus minimizing the impact of adverse effects on patients’
lives.
Agenda
- Prevalence of major antidepressant adverse effects
- Common adverse effects of antidepressants
- Case study, sexual dysfunction
- Case study, weight gain
- Antidepressant comparative tolerability
- Strategies for managing antidepressant adverse effects
Faculty

Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania
Conflict of Interest Policy/Disclosure Statement
Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Advisory/Consultant: Acadia, Inc.; Akili, Inc.; Alkermes PLC;
Allergan, Inc. (Forest, Naurex); Clexio Biosciences, Ltd.; H. Lundbeck, A/S;
Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.;
Otsuka Pharmaceutical Company, Ltd.; Pfizer, Inc.; Seelos
Grant Support: Acadia, Inc.; Allergan, Inc.; Axsome Therapeutics
Inc.; Intracellular, Inc.; Johnson & Johnson (Janssen); Otsuka Pharmaceutical
Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI);
Takeda
Royalties: American Psychiatric Press; Guilford Publications; Herald
House; W.W. Norton & Company, Inc.; Wolters Kluwer
CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.
Accreditation Statement
This
activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of
Medical Education Resources (MER) and CMEology. MER is accredited by the
ACCME to provide continuing medical education for physicians.
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CE activity provides 0.5 contact hour(s) of continuing nursing education.
Instructions for Receiving Credit
There are no fees for participating in and receiving credit for this activity. During the period January 25, 2022 through January 25, 2023, participants must (1) read the learning objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest
Activity Details
0.5 Contact Hour(s)
Expires: January 25, 2023
Jointly Provided By
This activity is jointly provided by Medical Education Resources and CMEology.
Target Audience
Psychiatrists and advanced practice psychiatry clinicians who care for patients with major depressive disorder.
Learning Objectives
- Evaluate patients being treated for MDD to identify common adverse effects such as sexual dysfunction, weight gain, and sleep disturbance
- Assess treatment strategies for a patient with MDD who is experiencing an adverse effect on their current MDD therapy
Activity Description
This is one of two related online multimedia activities designed to assess and enhance clinical decision-making through immersive, interactive learning. Participants will use realistic “near-life” education as they make decisions for what comes next – just like real life.
Statement of Educational Need
Adverse effects associated with antidepressants are common. In addition to compromising patients’ health and quality of life, they are one of the most common reasons that individuals with MDD fail to adhere to their treatment plans. To minimize the impact of antidepressant side effects on the lives of patients with MDD, clinicians require education on how to prevent, detect, and manage the most common adverse effects caused by these medications. In this activity, an expert faculty member will support learners as they are asked to respond to patients experiencing side effects related to their antidepressant use. Two cases will be used to illustrate how a patient-centered approach to MDD care can maximize treatment tolerability.
Learning Goal/Purpose
The goal of this activity is to increase clinicians’ knowledge and competence
with regard to preventing, detecting, and managing antidepressant side
effects, thus minimizing the impact of adverse effects on patients’
lives.
Agenda
- Prevalence of major antidepressant adverse effects
- Common adverse effects of antidepressants
- Case study, sexual dysfunction
- Case study, weight gain
- Antidepressant comparative tolerability
- Strategies for managing antidepressant adverse effects
Faculty

Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania
Conflict of Interest Policy/Disclosure Statement
Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Advisory/Consultant: Acadia, Inc.; Akili, Inc.; Alkermes PLC;
Allergan, Inc. (Forest, Naurex); Clexio Biosciences, Ltd.; H. Lundbeck, A/S;
Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.;
Otsuka Pharmaceutical Company, Ltd.; Pfizer, Inc.; Seelos
Grant Support: Acadia, Inc.; Allergan, Inc.; Axsome Therapeutics
Inc.; Intracellular, Inc.; Johnson & Johnson (Janssen); Otsuka Pharmaceutical
Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI);
Takeda
Royalties: American Psychiatric Press; Guilford Publications; Herald
House; W.W. Norton & Company, Inc.; Wolters Kluwer
CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.
Accreditation Statement
This
activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of
Medical Education Resources (MER) and CMEology. MER is accredited by the
ACCME to provide continuing medical education for physicians.
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CE activity provides 0.5 contact hour(s) of continuing nursing education.
Instructions for Receiving Credit
There are no fees for participating in and receiving credit for this activity. During the period January 25, 2022 through January 25, 2023, participants must (1) read the learning objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest

Finding the Path in Eosinophilic Esophagitis: Interdisciplinary Strategies for Adult and Pediatric Patients
StartActivity Details
1.25 AANP contact hour(s)
Expires: December 10, 2022
Provided By
This activity is jointly provided by Global Education Group and Integritas Communications.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
Target Audience
This program is intended for allergists/clinical immunologists, gastroenterologists, and other clinicians involved in the identification and management of patients with eosinophilic esophagitis (EoE).
Program Overview
During this Call-a-Colleague™ program, specialists in allergy/immunology and eosinophilic gastrointestinal disease will discuss the disease burden, pathophysiology, diagnosis, and current management of EoE. Faculty will also present clinical trial evidence for emerging treatment options as well as considerations for patients with other atopic conditions. A unique feature of the program will be the Call-a-Colleague™ sections in which our specialists will elicit additional insight from their multidisciplinary team members, such as a dietitian, a psychologist, and a pediatric gastroenterologist. The clinicians will provide their expertise regarding the mental health burden among patients, the use of an elimination diet to resolve symptoms, and clinical issues pertaining to pediatric patients with EoE.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe the pathophysiologic mechanisms underlying EoE development, with a focus on potential therapeutic targets
- Comprehensively assess pediatric and adult patients with suspected EoE to accelerate differential diagnoses and establish appropriate multidisciplinary care
- Compare the clinical profiles, available trial evidence, and drawbacks of current and emerging treatment strategies for EoE
- Longitudinally manage pediatric and adult patients with EoE based on symptoms, comorbidities, updated clinical guidelines, and therapeutic responses
- Communicate with patients, caregivers, and members of the multidisciplinary team to ensure continuity of care and promote shared clinical decision-making
Faculty

Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

Professor of Medicine (Gastroenterology and Hepatology)
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Chief, Allergy Program
Children's Hospital of Philadelphia
Stuart E. Starr Chair of Pediatrics
Professor of Pediatrics
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and
implemented in accordance with the Accreditation Standards of the American
Association of Nurse Practitioners (AANP) through the joint providership of
Global Education Group and Integritas Communications. Global Education Group
is accredited by the American Association of Nurse Practitioners as an
approved provider of nurse practitioner continuing education. Provider
number: 110121. This activity is approved for 1.25 contact hour(s) (which
includes 0.0 hour(s) of pharmacology).
Instructions to Receive Credit
In order to receive credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Preactivity Questions.
- Review the activity content.
- Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation to receive credit.
Term of Offering
This activity was released on December 10, 2021, and is valid for one year. Requests for credit must be made no later than December 10, 2022.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Mirna Chehade, MD
Consulting Fee: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc.,
Bristol Myers Squibb, Ellodi Pharmaceuticals, Phathom Pharmaceuticals
Regeneron Pharmaceuticals, Inc., Sanofi S.A, Shire plc, Takeda Pharmaceutical
Company Limited.
Contracted Research: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc,
Danone S.A., Ellodi Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Shire
plc, Takeda Pharmaceutical Company Limited.
Ikuo Hirano, MD
Consultant: Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Avir,
Celgene/Receptos/BMS, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calyx,
Regeneron, Shire/Takeda.
Research funding: Adare/Ellodi, Allakos, AstraZeneca, Celgene/Receptos/BMS,
Meritage, Regeneron, Shire/Takeda.
Jonathan Spergel, MD
Consultant: Abbott, Novartis, Regeneron, Sanofi.
Research funding: Celgene, Genentech, Novartis, Regeneron, Sanofi.
The planners and managers have the following relevant financial relationships with ineligible companies:
Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Kim Rodriguez - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose
Rose O’Connor, PhD, CHCP - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
1.25 AANP contact hour(s)
Expires: December 10, 2022
Provided By
This activity is jointly provided by Global Education Group and Integritas Communications.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
Target Audience
This program is intended for allergists/clinical immunologists, gastroenterologists, and other clinicians involved in the identification and management of patients with eosinophilic esophagitis (EoE).
Program Overview
During this Call-a-Colleague™ program, specialists in allergy/immunology and eosinophilic gastrointestinal disease will discuss the disease burden, pathophysiology, diagnosis, and current management of EoE. Faculty will also present clinical trial evidence for emerging treatment options as well as considerations for patients with other atopic conditions. A unique feature of the program will be the Call-a-Colleague™ sections in which our specialists will elicit additional insight from their multidisciplinary team members, such as a dietitian, a psychologist, and a pediatric gastroenterologist. The clinicians will provide their expertise regarding the mental health burden among patients, the use of an elimination diet to resolve symptoms, and clinical issues pertaining to pediatric patients with EoE.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe the pathophysiologic mechanisms underlying EoE development, with a focus on potential therapeutic targets
- Comprehensively assess pediatric and adult patients with suspected EoE to accelerate differential diagnoses and establish appropriate multidisciplinary care
- Compare the clinical profiles, available trial evidence, and drawbacks of current and emerging treatment strategies for EoE
- Longitudinally manage pediatric and adult patients with EoE based on symptoms, comorbidities, updated clinical guidelines, and therapeutic responses
- Communicate with patients, caregivers, and members of the multidisciplinary team to ensure continuity of care and promote shared clinical decision-making
Faculty

Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

Professor of Medicine (Gastroenterology and Hepatology)
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Chief, Allergy Program
Children's Hospital of Philadelphia
Stuart E. Starr Chair of Pediatrics
Professor of Pediatrics
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and
implemented in accordance with the Accreditation Standards of the American
Association of Nurse Practitioners (AANP) through the joint providership of
Global Education Group and Integritas Communications. Global Education Group
is accredited by the American Association of Nurse Practitioners as an
approved provider of nurse practitioner continuing education. Provider
number: 110121. This activity is approved for 1.25 contact hour(s) (which
includes 0.0 hour(s) of pharmacology).
Instructions to Receive Credit
In order to receive credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Preactivity Questions.
- Review the activity content.
- Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation to receive credit.
Term of Offering
This activity was released on December 10, 2021, and is valid for one year. Requests for credit must be made no later than December 10, 2022.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Mirna Chehade, MD
Consulting Fee: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc.,
Bristol Myers Squibb, Ellodi Pharmaceuticals, Phathom Pharmaceuticals
Regeneron Pharmaceuticals, Inc., Sanofi S.A, Shire plc, Takeda Pharmaceutical
Company Limited.
Contracted Research: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc,
Danone S.A., Ellodi Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Shire
plc, Takeda Pharmaceutical Company Limited.
Ikuo Hirano, MD
Consultant: Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Avir,
Celgene/Receptos/BMS, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calyx,
Regeneron, Shire/Takeda.
Research funding: Adare/Ellodi, Allakos, AstraZeneca, Celgene/Receptos/BMS,
Meritage, Regeneron, Shire/Takeda.
Jonathan Spergel, MD
Consultant: Abbott, Novartis, Regeneron, Sanofi.
Research funding: Celgene, Genentech, Novartis, Regeneron, Sanofi.
The planners and managers have the following relevant financial relationships with ineligible companies:
Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Kim Rodriguez - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose
Rose O’Connor, PhD, CHCP - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 6: Neuropsychological and Cognitive Changes
StartActivity Details
0.25 Contact Hour(s)
Expires: December 8, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Tailor antiretroviral therapy (ART) regimens according to patient comorbidities, risk factors, adverse events, and drug−drug interactions
Activity Description
Mental health comorbidities, particularly depression, are common in HIV. Clinicians who treat patients with HIV often lack experience in pharmacologic treatment of depression or other mental health disorders. Dr. Richard A. Elion and Dr. Glenn Jordan Treisman discuss a patient with worsening depression and chronic pain in terms of screening for her depression, the relationship between depression and chronic pain, and both nonpharmacologic and pharmacologic options to treat her depression.
Faculty

Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia

Director, AIDS Psychiatry Service
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies
Glenn Jordan Treisman, MD, PhD: Nothing to disclose
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or
at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Activity Details
0.25 Contact Hour(s)
Expires: December 8, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Tailor antiretroviral therapy (ART) regimens according to patient comorbidities, risk factors, adverse events, and drug−drug interactions
Activity Description
Mental health comorbidities, particularly depression, are common in HIV. Clinicians who treat patients with HIV often lack experience in pharmacologic treatment of depression or other mental health disorders. Dr. Richard A. Elion and Dr. Glenn Jordan Treisman discuss a patient with worsening depression and chronic pain in terms of screening for her depression, the relationship between depression and chronic pain, and both nonpharmacologic and pharmacologic options to treat her depression.
Faculty

Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia

Director, AIDS Psychiatry Service
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies
Glenn Jordan Treisman, MD, PhD: Nothing to disclose
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or
at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 5: Controversies in Managing Resistance
StartActivity Details
0.25 Contact Hour(s)
Expires: December 3, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure
Activity Description
Though first-line antiretroviral therapy (ART) regimens have high barriers to resistance, it is still important to obtain genotyping for newly diagnosed patients and for those experiencing virologic failure. There is evidence that patients with a variety of resistance mutations can still achieve viral suppression, though regimen selection may be influenced by resistance mutations. Dr. Richard A. Elion and Dr. Jürgen Rockstroh discuss a newly diagnosed patient with baseline resistance mutations in the context of treatment initiation, switching, impact of specific mutations, and how resistance mutations influence selection of either 2-drug or long-acting therapies.
Faculty

Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia

Professor of Medicine
Head of the HIV Outpatient Clinic
University of Bonn
Bonn, Germany
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies
Jürgen Rockstroh, MD: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., Theratechnologies Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or
at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Activity Details
0.25 Contact Hour(s)
Expires: December 3, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure
Activity Description
Though first-line antiretroviral therapy (ART) regimens have high barriers to resistance, it is still important to obtain genotyping for newly diagnosed patients and for those experiencing virologic failure. There is evidence that patients with a variety of resistance mutations can still achieve viral suppression, though regimen selection may be influenced by resistance mutations. Dr. Richard A. Elion and Dr. Jürgen Rockstroh discuss a newly diagnosed patient with baseline resistance mutations in the context of treatment initiation, switching, impact of specific mutations, and how resistance mutations influence selection of either 2-drug or long-acting therapies.
Faculty

Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia

Professor of Medicine
Head of the HIV Outpatient Clinic
University of Bonn
Bonn, Germany
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies
Jürgen Rockstroh, MD: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., Theratechnologies Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or
at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 4: Heavily Treatment-Experienced Patients
StartActivity Details
0.25 Contact Hour(s)
Expires: December 3, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objectives
After completing this activity, the participant should be better able to:
- Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure
- Review recent data on new and emerging ART regimens
Activity Description
As patients with HIV live longer, clinicians must work with heavily treatment-experienced patients who are experiencing virologic failure and have few treatment options left. Though this is a small population, their subsequent antiretroviral therapy (ART) regimens should be tailored carefully and may need to employ new ART agents as they become available. Dr. Chloe Orkin and Dr. Jonathan Schapiro discuss a heavily treatment-experienced patient in the context of resistance mutations, Stanford score, considerations for subsequent regimens, and new and emerging options for these patients.
Faculty

Consultant Physician and Lead for HIV Research
Professor of HIV Medicine
Queen Mary University of London and Barts Health NHS Trust
Director, SHARE Collaborative
Academic Lead for Equality, Diversity, and Inclusion SMD
President, Medical Women’s Federation
London, United Kingdom

Director
HIV/AIDS Clinic
National Hemophilia Center
Sheba Medical Center
Tel Aviv, Israel
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Chloe Orkin, MBBCH, MSc, FRCP: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare
Jonathan Schapiro, MD: Consulting Fees: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Contracted Research: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Speakers Bureau: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or
at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Activity Details
0.25 Contact Hour(s)
Expires: December 3, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objectives
After completing this activity, the participant should be better able to:
- Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure
- Review recent data on new and emerging ART regimens
Activity Description
As patients with HIV live longer, clinicians must work with heavily treatment-experienced patients who are experiencing virologic failure and have few treatment options left. Though this is a small population, their subsequent antiretroviral therapy (ART) regimens should be tailored carefully and may need to employ new ART agents as they become available. Dr. Chloe Orkin and Dr. Jonathan Schapiro discuss a heavily treatment-experienced patient in the context of resistance mutations, Stanford score, considerations for subsequent regimens, and new and emerging options for these patients.
Faculty

Consultant Physician and Lead for HIV Research
Professor of HIV Medicine
Queen Mary University of London and Barts Health NHS Trust
Director, SHARE Collaborative
Academic Lead for Equality, Diversity, and Inclusion SMD
President, Medical Women’s Federation
London, United Kingdom

Director
HIV/AIDS Clinic
National Hemophilia Center
Sheba Medical Center
Tel Aviv, Israel
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Chloe Orkin, MBBCH, MSc, FRCP: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare
Jonathan Schapiro, MD: Consulting Fees: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Contracted Research: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Speakers Bureau: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or
at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.

CMV Perils in Transplant Recipients: Prevention, Resistance, and Safety Considerations – A Care Team Forum℠
StartActivity Details
0.75 ABIM MOC Point(s)
Expires: November 8, 2022
Provided By
This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.
Target Audience
This activity is intended for infectious disease specialists (MD/DO/NP/PA) and other clinicians who manage solid organ or hematopoietic cell transplant patients with cytomegalovirus (CMV).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Recognize the importance of early cytomegalovirus (CMV) prophylaxis in hematopoietic stem cell transplant patients
- Identify risk factors and emerging therapies for resistant CMV disease in solid organ transplant and hematopoietic stem cell transplant patients
- Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
Activity Description
In this activity, Drs. Kotton, Chemaly, and Silveira share insights on cytomegalovirus (CMV) prevention and emerging treatments for resistant and refractory CMV disease. Learn tips for avoiding and managing side effects of antiviral therapies. Hear first-hand from a transplant patient who shares his difficult journey with resistant CMV disease.

Statement of Educational Need
Although hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) are essential and often lifesaving, they are associated with potentially life-threatening opportunistic infections. Specifically, cytomegalovirus (CMV) infection is one of the most common infectious complications in patients undergoing HCT and SOT. Greater than 50% of solid organ transplant recipients may display evidence of CMV replication, and 10% to 50% may progress to symptomatic disease. CMV increases mortality risk and may cause organ damage even in the absence of obvious CMV disease. Current CMV antiviral treatments are limited by significant hematologic and renal toxicities, as well as resistance. Strategies to overcome these limitations, including novel antiviral therapies, vaccines, and T-cell therapies, offer hope for transplant patients who face the serious threat of CMV.
Faculty

Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Professor of Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research
UT MD Anderson Cancer Center
Houston, TX

Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Merck (Adjudication Committee Member); Evrys, Hookipa, Merck, Oxford Immunotec, Shire/Takeda, Synklino (Consulting Fees); AiCuris, Hookipa, Oxford Immunotec (Contracted Research); Hookipa (Principal Investigator); Merck, Oxford Immunotec, Shire/Takeda (Speaker Bureau).
Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ, has affiliations with ADMA Biologics, Adagio, Ansun, Genentech, Janssen, Merck, Molecular Partners, Oxford Immunotec, Takeda (Consulting Fees); AiCuris, Ansun, Genentech, Janssen, Karius, Merck, Oxford Immunotec, Takeda, Viracor (Contracted Research).
Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Takeda (Consulting Fees); Ansun, Gilead, Novartis, Qiagen, Shire, SlieaGen (Contracted Research).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical
Education, LLC planners and managers have nothing to disclose.
Joint Accreditation Statement
In support of improving
patient care, this activity has been planned and implemented by the
Postgraduate Institute for Medicine and RMEI Medical Education, LLC.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of
this CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 0.75 MOC point(s) in the American Board
of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.
Participants will earn MOC points equivalent to the amount of CME credits
claimed for the activity. It is the CME activity provider’s responsibility to
submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
During the period from November 9, 2021 through November 8, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
If you have questions regarding the certification of this activity, please contact PIM via e-mail at inquiries@pimed.com.
Activity Details
0.75 ABIM MOC Point(s)
Expires: November 8, 2022
Provided By
This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.
Target Audience
This activity is intended for infectious disease specialists (MD/DO/NP/PA) and other clinicians who manage solid organ or hematopoietic cell transplant patients with cytomegalovirus (CMV).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Recognize the importance of early cytomegalovirus (CMV) prophylaxis in hematopoietic stem cell transplant patients
- Identify risk factors and emerging therapies for resistant CMV disease in solid organ transplant and hematopoietic stem cell transplant patients
- Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
Activity Description
In this activity, Drs. Kotton, Chemaly, and Silveira share insights on cytomegalovirus (CMV) prevention and emerging treatments for resistant and refractory CMV disease. Learn tips for avoiding and managing side effects of antiviral therapies. Hear first-hand from a transplant patient who shares his difficult journey with resistant CMV disease.

Statement of Educational Need
Although hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) are essential and often lifesaving, they are associated with potentially life-threatening opportunistic infections. Specifically, cytomegalovirus (CMV) infection is one of the most common infectious complications in patients undergoing HCT and SOT. Greater than 50% of solid organ transplant recipients may display evidence of CMV replication, and 10% to 50% may progress to symptomatic disease. CMV increases mortality risk and may cause organ damage even in the absence of obvious CMV disease. Current CMV antiviral treatments are limited by significant hematologic and renal toxicities, as well as resistance. Strategies to overcome these limitations, including novel antiviral therapies, vaccines, and T-cell therapies, offer hope for transplant patients who face the serious threat of CMV.
Faculty

Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Professor of Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research
UT MD Anderson Cancer Center
Houston, TX

Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Merck (Adjudication Committee Member); Evrys, Hookipa, Merck, Oxford Immunotec, Shire/Takeda, Synklino (Consulting Fees); AiCuris, Hookipa, Oxford Immunotec (Contracted Research); Hookipa (Principal Investigator); Merck, Oxford Immunotec, Shire/Takeda (Speaker Bureau).
Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ, has affiliations with ADMA Biologics, Adagio, Ansun, Genentech, Janssen, Merck, Molecular Partners, Oxford Immunotec, Takeda (Consulting Fees); AiCuris, Ansun, Genentech, Janssen, Karius, Merck, Oxford Immunotec, Takeda, Viracor (Contracted Research).
Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Takeda (Consulting Fees); Ansun, Gilead, Novartis, Qiagen, Shire, SlieaGen (Contracted Research).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical
Education, LLC planners and managers have nothing to disclose.
Joint Accreditation Statement
In support of improving
patient care, this activity has been planned and implemented by the
Postgraduate Institute for Medicine and RMEI Medical Education, LLC.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of
this CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 0.75 MOC point(s) in the American Board
of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.
Participants will earn MOC points equivalent to the amount of CME credits
claimed for the activity. It is the CME activity provider’s responsibility to
submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
During the period from November 9, 2021 through November 8, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
If you have questions regarding the certification of this activity, please contact PIM via e-mail at inquiries@pimed.com.

Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient
StartActivity Details
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Expires: October 10, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who may be at high risk for influenza-related complications
- Recognize the possible presentations of influenza in high-risk individuals
- Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
- Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza
Activity Description
In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.
Activity Chair

Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty

Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); AiCurus, Janssen, GlaxoSmithKline, Shire (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).
Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical
Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.25 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
- Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Expires: October 10, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients who may be at high risk for influenza-related complications
- Recognize the possible presentations of influenza in high-risk individuals
- Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
- Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza
Activity Description
In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.
Activity Chair

Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty

Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); AiCurus, Janssen, GlaxoSmithKline, Shire (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).
Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical
Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for
0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy
Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 0.25 medical knowledge MOC point(s) in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
- Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
- Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.